31 October 2014 | News | By BioSpectrum Bureau
Fujifilm to acquire US-based vaccine maker
Fujilfilm may increase its stake upto 100 percent based on achievement of certain milestones
Singapore: Japan's Fujifilm has inked a deal to acquire US-based Kalon Bio therapeutics, which has expertise in manufacturing vaccines used against pandemic influenza, Ebola and other public-health threats.
Fujifilm Diosynth Biotechnologies said in a statement that they may increase the stake to 100 percent after the initial closing based on achievement of certain milestones. The purchase amount was not disclosed.
For long, Fujifilm has been focusing to nurture its healthcare and biotechnology business with strategic acquisitions. In 2008, the company acquired Toyama Chemicals, whose influenza drug Avigan has been drafted to the fight against Ebola.
Kalon's unique vaccine manufacturing strategy using mammalian cell culture technology enables safe, stable manufacture of vaccines to be used as public medical counter measures against threats such as pandemic influenza, Ebola,and Anthrax.